Xiclav® 250: Each  film  coated  tablet  contains  Cefuroxime  Axetil  USP  equivalent  to  Cefuroxime  250  mg and Potassium Clavulanate BP equivalent to Clavulanic Acid 62.5 mg.
Xiclav® 500:  Each  film  coated  tablet  contains  Cefuroxime  Axetil  USP  equivalent  to  Cefuroxime  500  mg and Potassium Clavulanate BP equivalent to Clavulanic Acid 125 mg.
Xiclav® Granules for Suspension: Each 5 ml of reconstituted suspension contains Cefuroxime Axetil USP equivalent to Cefuroxime 125 mg and Potassium Clavulanate BP equivalent to Clavulanic Acid 31.25 mg.

Cefuroxime is a broad-spectrum second generation cephalosporin which is active against both gram (+)ve  &  gram  (-)ve  aerobes  and  also  anerobes.  It  has  bactericidal  activity  against  a  wide  range  of common  pathogens  including  beta-lactamase  producing  strains.  It  is  indicated  for  the  treatment  of  infections caused by sensitive bacteria.
Clavulanic  acid  has  a  similar  structure  to  the  beta-lactam  antibiotics  but  binds  irreversibly  to  the  beta-lactamase  enzymes  and  inactivates  them.  Clavulanic  acid  in  Xiclav® gives  protection  of cefuroxime  from  degradation  by  beta-lactamase  enzyme  and  provides  a  solution  for  treatment  of  
bacterial infections caused by beta lactam resistant pathogens.

Storage
Store at controlled room temperature, 20-25 °C (68-77 °F), avoid freezing and protect from light.

• Pharyngitis/Tonsillitis caused by Streptococcus pyogenes.
• Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Moraxella catarrhalis (including beta-lactamase-producing strains), or  Streptococcus pyogenes
• Acute  Bacterial  Maxillary  Sinusitis  caused  by Streptococcus  pneumoniae or Haemophilus influenzae (non-beta-lactamase-producing strains only)
• Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis  caused  by Streptococcus  pneumoniae, Haemophilus  influenzae (beta-lactamase  negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains)
• Skin  and  Skin-Structure  Infections  caused  by Staphylococcus  aureus (penicillinase-  and  non-penicillinase-producing  strains), Streptococcus  pyogenes,  Escherichia  coli,  Klebsiella  spp and Enterobacter spp
• Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae
• Gonorrhea: Uncomplicated and disseminated gonococcol infections due to Neiseria gonorrheae (penicillinase- and non-penicillinase-producing strains), in both males and females
• Early Lyme disease (erythema migrans) caused by Borrelia burgdorferi
• Impetigo  caused  by  Staphylococcus  aureus  (including  beta-lactamase-producing  strains)  or Streptococcus pyogenes.
• Switch therapy (injectable to oral) after surgery when patients condition is improved

Xiclav® should be taken after food for optimum absorption.

Xiclav® Tablet

Generally cefuroxime and clavulanic acid are well tolerated. However, a few side effects like nausea, vomiting, diarrhoea,  abdominal  discomfort  or  pain  may  occur.  As  with  other  broad-spectrum  antibiotics,  prolonged  administration  of  cefuroxime  &  clavulanic  acid  combination  may  result  in  overgrowth  of  nonsusceptible  microorganisms.  Rarely  (<0.20%)  renal  dysfunction,  anaphylaxis,  angioedema,  pruritis,  rash  and  serum  sickness like urticaria may appear.

Xiclav® should  be  given  with  care  to  patients  receiving  concurrent  treatment  with  potent  diuretics  and  who have history of colitis

Patients with known hypersensitivity to cephalosporins & pseudomembraneous colitis are contraindicated.

During Pregnancy: While all antibiotics should be avoided in the first trimester if possible, however Xiclav® can be safely used in later pregnancy to treat urinary and other infections. During lactation: Because Xiclav® is excreted into the breast milk in small quantities. However, the possibility of sensitizing the infant should be kept in mind.

Xiclav® 250mg Tablet: Each box contains 1x10's tablets in Tropical blister (Alu-PVC-Alu) pack.
Xiclav® 500mg Tablet: Each box contains 1x10's tablets in Tropical blister (Alu-PVC-Alu) pack. Xiclav® Granules  for  Suspension:  Each  carton  contains  a  large  bottle  containing  Cefuroxime  and  Clavulanic  acid  dry  granules  for  reconstituting  70  ml  of  suspension  and  a  small  bottle  containing  diluents  along  with  a  measuring cup, a spoon and a dropper

Probenecid increases Xiclav® blood levels; drugs lowering gastric acidity may decrease Xiclav®bioavailability.
Overdosage :
Signs  and  symptoms:  Overdosage  of Xiclav®  can  cause  cerebral  irritation  leading  to  convulsions.  
Management: Serum levels of Xiclav® can be reduced by haemodialysis and peritoneal dialysis.

Xiclav® Tablet : Store in a cool & dry place, protected from light.
Xiclav®  Granules  for  suspension  :  Before  reconstitution,  store  dry  granules  between  2degree  &  30degree C.  After reconstitution immediately store suspension between 2degree & 8degree C in a refrigerator. Discard after 07 days.